| Literature DB >> 29891794 |
Ahmed Sekkien1, Noha Swilam2, Sherif S Ebada3, Ahmed Esmat4, Ahmed H El-Khatib5,6, Michael W Linscheid7, Abdel Nasser Singab8.
Abstract
Tamarix nilotica (Ehrenb.) Bunge (Tamaricaceae), an indigenous plant to the Middle East region, is well-known as a medicinal plant for treating many human ailments. The current study aimed at exploring the polyphenol profile of the alcohol soluble fraction of aqueous T. nilotica extract, assessing its in vivo antifibrotic activity and the possible underlying mechanism, to unravel the impact of quantitative difference of sulphated polyphenols content on the antifibrotic activity of T. nilotca grown in two different habitats. Polyphenol profiling of T. nilotica extracts was performed using HPLC-HRESI-QTOF-MS-MS. The major polyphenol components included sulphated flavonoids, phenolic acids and free aglycones. The antifibrotic activity was evaluated through carbon tetrachloride-induced liver fibrosis in rats. Biochemical evaluations revealed that both fractions ameliorated the increased levels of hepatic aminotransferases, lipid peroxidation, hydroxyproline, α-smooth muscle actin (α-SMA), tumor necrosis factor-α (TNF-α), cyclooxygenase-2 (COX-2) and nuclear factor kappa B (NF-κB). Moreover, both fractions reduced catalase activity (CAT) and enhanced hepatic glutathione (GSH) content. Histopathological imaging undoubtedly confirmed such results. In conclusion, the T. nilotica polyphenol-rich fraction exhibited potential antifibrotic activity in rats. Significant alterations in GSH levels were recorded based on the sulphated polyphenol metabolite content.Entities:
Keywords: HPLC/HRESI/MS/MS; Tamaricaceae; Tamarix nilotica; antifibrotic activity; polyphenols
Mesh:
Substances:
Year: 2018 PMID: 29891794 PMCID: PMC6100050 DOI: 10.3390/molecules23061411
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Characterization of metabolites from ETN by HPLC-MS/MS in negative ion mode.
| # | Rt (Min) | [M − H]− | Error (ppm) | MS/MS Fragment | Formula | Identity | References |
|---|---|---|---|---|---|---|---|
| 1 | 3.9 | 169.0220 | −2.9 | 125.1086 | C7H6O5 | Gallic acid | [ |
| 2 | 4.12 | 301.0421 | 1.6 | 273.0435, 179.0096, 150.9980 | C15H10O7 | Quercetin | [ |
| 3 | 6.59 | 483.0859 | −1.2 | 331.1573, 313.1711, 169.1114 | C20H20O14 | di-Galloyl-glucose (nilocitin) | [ |
| 4 | 14.72 | 285.0469 | 2.8 | 239.0530, 143.1847 | C15H10O6 | Kaempferol | [ |
| 5 | 28.09 | 197.0531 | −1.5 | 183.2035, 182.1017, 168.1108, 167.1539 | C9H10O5 | Methyl gallate methyl ether | [ |
| 6 | 30.61 | 259.0356 | −0.8 | 229.0872, 179.0628, | C10H12O6S | Coniferyl alcohol sulphate | [ |
| 7 | 36.82 | 193.0574 | 2.6 | 178.1750, 149.1777, 134.0983 | C10H10O4 | Ferulic acid isomer | [ |
| 8 | 42.4 | 477.1101 | 2.1 | 315.0990, 300.1015 | C22H22O12 | Methylquercetin hexoside (tamarixetin-3- | [ |
| 9 | 43.93 | 273.0145 | 0.7 | 229.0810, 193.1538, 178.0940 | C10H10O7S | Ferulic acid sulphate derivative | [ |
| 10 | 53.62 | 314.1315 | −0.32 | 177.0162, 164.1282, 145.1110 | C18H19NO4 | [ | |
| 11 | 57.08 | 287.0299 | 1.4 | 272.1937, 207.1997, 192.1747 | C11H12O7S | Methyl ferulate sulphate | [ |
| 12 | 58.3 | 461.0806 | −1.7 | 285.1083, 257.3536 | C21H18O12 | Kaempferol glucuronide | [ |
| 13 | 67.53 | 315.0587 | −1.3 | 300.1302, 193.1954 | C16H12O7 | Methylquercetin (tamarixetin) | [ |
| 14 | 71.19 | 299.0624 | 3 | 284.1601, 271.2777 | C16H12O6 | Methylkaempferol (kaempferide) | [ |
| 15 | 74.7 | 395.0154 | −0.8 | 315.1095, 300.2426, 217.0871 | C16H12O10S | Methylquercetin-sulphate (tamarixetin sulphate) | [ |
| 16 | 75.12 | 379.0195 | 1.8 | 299.1220, 284.2777 | C16H12O9S | Kaempferol methyl ether sulphate | [ |
| 17 | 75.89 | 393.0366 | −2 | 313.1219, 298.0152, 283.8303 | C17H14O9S | Kaempferol dimethyl ether sulphate | [ |
* Detected only through inspection of the positive ion mode. ETN is the alcohol soluble fraction of aqueous extract of T. nilotica from Egypt.
Characterization of metabolites from STN by HPLC-MS/MS in negative ion mode.
| # | Rt (Min) | [M − H]− | Error (ppm) | MS/MS Fragment | Formula | Identity | References |
|---|---|---|---|---|---|---|---|
| 1 | 3.97 | 169.0213 | 1.18 | 125.1079 | C7H6O5 | Gallic acid | [ |
| 2 | 4.17 | 301.0425 | 0.33 | 273.0441, 179.0084, 150.9916 | C15H10O7 | Quercetin | [ |
| 3 | 6.47 | 483.0851 | 0.41 | 331.1561, 313.1709, 169.1116 | C20H20O14 | di-Galloylglucose (nilocitin) | [ |
| 4 | 14.79 | 285.0483 | −2.10 | 239.0536, 143.1841 | C15H10O6 | Kaempferol | [ |
| 5 | 28.13 | 197.0533 | −2.52 | 183.2027, 182.1022, 168.1119, 167.1531 | C9H10O5 | Methyl gallate methyl ether | [ |
| 6 | 30.45 | 259.0351 | 1.15 | 229.0876, 179.0632 | C10H12O6S | Coniferyl alcohol sulphate | [ |
| 7 | 43.98 | 273.0151 | −1.46 | 229.0806, 193.1527, 178.0947 | C10H10O7S | Ferulic acid sulphate derivative | [ |
| 8 | 53.72 | 314.1319 | −1.60 | 177.0161, 164.12874, 145.1103 | C18H19NO4 | [ | |
| 9 | 56.93 | 287.0301 | 0.69 | 272.1925, 207.2002, 192.1733 | C11H12O7S | Methyl ferulate sulphate | [ |
| 10 | 58.20 | 461.0795 | 0.65 | 285.1096, 257.3548 | C21H18O12 | Kaempferol glucruonide | [ |
| 11 | 67.77 | 315.0589 | −1.90 | 300.1311, 193.1967 | C16H12O7 | Methyl-quercetin (Tamarixetin) | [ |
| 12 | 71.17 | 299.0629 | 1.33 | 284.1607, 271.2769 | C16H12O6 | Methyl-kaempferol (Kaempferide) | [ |
| 13 | 74.65 | 395.0159 | −2.02 | 315.1085, 300.2417, 217.0865 | C16H12O10S | Methyl-quercetin-sulphate (Tamarixetin-sulphate) | [ |
| 14 | 75.14 | 379.0191 | 2.89 | 299.1221, 284.2782 | C16H12O9S | Kaempferol-methyl ether-sulphate | [ |
| 15 | 75.60 | 393.0368 | −2.54 | 313.1212, 298.0147, 283.8312 | C17H14O9S | Kaempferol-dimethyl ether-sulphate | [ |
* Detected only through inspection of the positive ion mode. STN is the alcohol soluble fraction of aqueous extract of T. nilotica from Saudi Arabia.
Total phenolic content of ETN and STN.
| Total Phenolic Content (mg GA/gm Dry Extract) | |
|---|---|
| ETN | 95.1 |
| STN | 111.8 |
Figure 1Radical scavenging activity of ETN and STN as compared to Trolox (as a positive control). Results are given as mean values ± SD of n = 3.
Figure 2Effect of ETN and STN on ALT (Panel A) and AST (Panel B) serum activities in rats subjected to chronic CCl4 intoxication. * Data are the mean ± SD (n = 10). a or b Significantly different from control or CCl4 group respectively at p < 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test.
Figure 3Representative photomicrographs of liver sections stained with (H&E) (100×). (A) Section taken from a control rat liver showing normal central vein and hepatic architecture; (B) Section taken from rat liver exposed to CCl4 showing thickening and fibrosis with fat cells deposition in the hepatic capsule associated with extended fibrosis to the hepatic parenchyma between the degenerated hepatocytes (arrowhead); (C) Section taken from rat liver exposed to CCl4 and treated with silymarin (100 mg/kg) showing restoration of normal histological structure; (D) Section taken from rat liver exposed to CCl4 and treated with ETN (100 mg/Kg) showing mild congestion in the central vein; (E) Section taken from rat liver exposed to CCl4 and treated with ETN (50 mg/Kg) showing portal vein congestion with inflammatory cells infiltration in the portal area; (F) Section taken from rat liver exposed only to ETN (100 mg/Kg) showing no histopathological alterations; (G) Section taken from rat liver exposed to CCl4 and treated with STN (100 mg/Kg) showing focal inflammatory cells infiltration (arrowheads); (H) Section taken from rat liver exposed to CCl4 and treated with STN (50 mg/Kg) showing diffuse inflammatory cells infiltration (arrowheads), with hepatocytes degeneration. (I) Section taken from rat liver exposed only to STN (100 mg/Kg) showing normal liver architecture.
Figure 4Effect of ETN and STN on hepatic GSH content (Panel A), lipid peroxidation as MDA concentration (Panel B); Catalase enzymatic activity (Panel C) in rats subjected to chronic CCl4 intoxication. * Data are the mean ± SD (n = 10). a or b: Significantly different from control or CCl4 group respectively at p < 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test.
Figure 5Effect of ETN and STN on liver hydroxyproline content rats subjected to chronic CCl4 intoxication. * Data are the mean ± SD (n = 6). a or b: Significantly different from control or CCl4 group respectively at p < 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test.
Figure 6Expression of alpha smooth muscle actin (α-SMA) by immunohistochemical staining (×100). (A) Photomicrograph of liver section of control rats showing minimal immunostaining for α-SMA; (B) Photomicrograph of liver section of CCl4 intoxicated rats showing extensive α-SMA expression of as shown by the intense brown staining; (C) Photomicrograph of liver section of (CCl4/Silymarin) treated rats showing limited α-SMA expression; (D) Photomicrograph of liver section of rats concurrently treated with CCl4 (1 mL/kg) twice a week and ETN (100 mg/kg) three times per week, showing limited α-SMA expression; (E) Photomicrograph of liver section of rats simultaneously treated with CCl4 (1 mL/kg) twice a week and STN (100 mg/Kg) three times per week, showing minimal α-SMA expression; (F) A graphical representation of the α-SMA expression as optical density (O.D) for the liver sections from different groups, where a or b express the significant difference from control or CCl4 group respectively at p < 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test.
Figure 7Effect of ETN and STN aqueous alcohol extracts on hepatic TNF-α (Panel A) and COX-2 content (Panel B) in rats subjected to chronic CCl4 intoxication. * Data are the mean ± SD (n = 6). a or b: Significantly different from control or CCl4 group respectively at p < 0.05 using ANOVA followed by Tukey-Kramer as a post-hoc test.
Figure 8Expression of nuclear factor kappa B (NF-κB) by immunohistochemical staining (100×). (A) Photomicrograph of liver section of control rats showing minimal immunostaining for NF-κB; (B) Photomicrograph of liver section of CCl4 intoxicated rats showing increased NF-κB expression of as shown by the intense brown staining; (C) Photomicrograph of liver section of (CCl4/silymarin) treated rats showing limited NF-κB expression; (D) Photomicrograph of liver section of rats concurrently treated with CCl4 (1 mL/Kg) twice a week and ETN (100 mg/Kg) three times per week, showing limited NF-κB expression; (E) Photomicrograph of liver section of rats simultaneously treated with CCl4 (1 mL/Kg) twice a week and STN (100 mg/Kg) three times per week, showing decreased NF-κB expression; (F) A graphical representation of the NF-κB expression as optical density (O.D) for the liver sections from different groups, where a or b express the significant difference from control or CCl4 group respectively at p < 0.05 using ONE-WAY ANOVA followed by Tukey-Kramer as a post-hoc test.